Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155
Open Access
- 28 October 2024
- journal article
- review article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 21 (14) , 2781-2798
Abstract
MicroRNAs (miRNAs)-based therapies hold great promise for cancer treatment, challenges such as expression variability, off-target effects, and limited clinical effectiveness have led to the withdrawal of many clinical trials. This review investigates the setbacks in miRNA-based therapies by examining miR-21, miR-34, and miR-155, highlighting their functional complexity, off-target effects, and the challenges in delivering these therapies effectively. Moreover, It highlights recent advances in delivery methods, combination therapies, and personalized treatment approaches to overcome these challenges. This review highlights the intricate molecular networks involving miRNAs, particularly their interactions with other non-coding RNAs, such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), emphasizing the pivotal role of miRNAs in cancer biology and therapeutic strategies. By addressing these hurdles, this review aims to steer future research toward harnessing the potential of miRNA therapies to target cancer pathways effectively, enhance anti-tumor responses, and ultimately improve patient outcomes in precision cancer therapy.Keywords
This publication has 117 references indexed in Scilit:
- Progress in microRNA deliveryJournal of Controlled Release, 2013
- Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensingNucleic Acids Research, 2012
- MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expressionCancer Gene Therapy, 2012
- microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancerOncology Letters, 2012
- The Oncogenic Role of miR-155 in Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2012
- miR-34 – a microRNA replacement therapy is headed to the clinicFrontiers in Genetics, 2012
- Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinomaMolecular Cancer, 2010
- ToppGene Suite for gene list enrichment analysis and candidate gene prioritizationNucleic Acids Research, 2009
- MicroRNA-Regulated Pathways Associated with EndometriosisMolecular Endocrinology, 2009
- Circular reasoning: microRNAs and cell-cycle controlTrends in Biochemical Sciences, 2008